Other News To Note
Wednesday, July 11, 2012
MDxHealth SA, of Liege, Belgium, said it expanded its collaboration with Merck KGaA, of Darmstadt, Germany, to cover the development and worldwide commercialization of MDxHealth's MGMT (methylguanine-DNA-methyltransferse) diagnostic test to identify glioblastoma patients who might be more likely to benefit from cilengitide, Merck's Phase III-stage integrin inhibitor.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.